# CRESEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cresen

- Industry: Medical Devices & Equipment
- Headquarters: Pleasanton, US
- Website: www.cresen.co/
- Total disclosed funding: $4.6M
- Latest round: Seed (Apr 7, 2026)
- Investors on record: 1

## About

CRESEN INC is a US-based company specializing in advanced surgical technologies, particularly known for its innovative Duoblade product that enhances surgical precision and minimizes collateral damage during operations.Founded in 2025, CRESEN INC is located in Pleasanton, US, and focuses on the development and commercialization of advanced surgical technology. The company has secured a total of KRW 7 billion through a SEED funding round raised on April 7, 2026, from Tony Investment and other investors. The funding aims to broaden customer reach and advance product development. The company has completed a single deal to date.Cresen focuses on the development and commercialization of advanced surgical technology, with its flagship product being the Duoblade. This innovative energy blade leverages Dielectric Ultra-focused Oscillatory (DUO) technology to provide surgeons with precision dissection capabilities while minimizing thermal damage to surrounding tissues. Released recently, Duoblade is designed to enhance surgical outcomes by reducing collateral damage, smoke, and improving visibility during operations. The primary clientele for Cresen includes hospitals, surgical centers, and medical professionals across the United States and Europe, where the demand for advanced surgical tools and techniques continues to grow. Cresen’s commitment to accessible innovation positions Duoblade as a critical solution for enhancing clinical practices and improving overall patient care.Cresen's revenue model is structured around direct sales of its Duoblade technology to healthcare facilities, including hospitals and surgical centers. Transactions typically occur through direct procurement agreements, where healthcare providers purchase units based on their surgical needs. The pricing structure for Duoblade reflects its advanced technology and is likely influenced by factors such as order volume and specific contractual agreements with healthcare entities. Additionally, Cresen may engage in partnerships with distributors to broaden its market reach, offering training and support services to enhance customer satisfaction and product utilization. This business model is designed to foster long-term relationships with healthcare providers, ensuring that they have access to cutting-edge surgical technology.In April 2026, CRESEN INC raised KRW 7 billion in Seed funding from new investor Tony Investment, which will be used to broaden the customer reach in the US and advance product development. The company plans to launch new products to enhance its surgical offerings and targets expansion into additional geographic regions to increase market penetration.

## Funding rounds

- Seed, Apr 7, 2026, $4.6M — Tony Investment

## Investors

- Tony Investment (https://capitalatlas.ai/funds/tony-investment) — Seed